Why is hyoscine (scopolamine or hyoscine butylbromide) administered to pregnant women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why Hyoscine is Given to Pregnant Women

Hyoscine (hyoscine butylbromide) is primarily administered to pregnant women as a labor analgesic and cervical spasmolytic agent to shorten the duration of active labor, not for typical gastrointestinal indications during pregnancy.

Primary Indication: Labor Management

Mechanism During Labor

  • Hyoscine butylbromide acts by inhibiting cholinergic transmission in the abdomino-pelvic parasympathetic ganglia, specifically targeting the cervico-uterine plexus to relieve smooth muscle spasm and aid cervical dilatation 1
  • The drug's anticholinergic action produces smooth-muscle relaxation in the female genital organs, facilitating labor progression 1, 2

Clinical Efficacy in Labor

  • Intravenous hyoscine butylbromide (40 mg) significantly shortens the active phase of labor by approximately 84 minutes compared to placebo 3
  • In primiparous women specifically, the reduction is approximately 55 minutes 3
  • Pain relief of up to 35.6% has been documented on visual analog scales when used during labor 1
  • Mean duration of labor was reduced from 8 hours 16 minutes (control) to 3 hours 46 minutes (treatment group) in one randomized trial 1

Safety Profile in Pregnancy

Maternal Safety

  • No adverse maternal effects were noted in clinical trials of hyoscine butylbromide use during labor 1
  • The drug has minimal systemic absorption (bioavailability <1% after oral administration), which limits systemic side effects 2
  • Hyoscine butylbromide does not penetrate the blood-brain barrier, reducing central nervous system effects 2

Fetal Safety

  • Neonatal outcomes were comparable between treatment and control groups, with no short-term adverse fetal effects documented 1
  • Mode of delivery was not adversely affected by hyoscine butylbromide administration 1

Important Clinical Caveats

Formulation Matters

  • Hyoscine butylbromide (quaternary ammonium compound) is poorly absorbed from the gastrointestinal tract and less likely to cross the blood-brain barrier compared to scopolamine (tertiary amine) 4
  • Intramuscular preparations may be more effective than oral formulations due to poor oral absorption 4

Scopolamine vs. Hyoscine Butylbromide

  • Scopolamine (the tertiary amine form) readily crosses the placenta and should be administered to pregnant women only under observation 5
  • Scopolamine is considered compatible with nursing and nonteratogenic, but requires more caution than hyoscine butylbromide 5

Timing of Administration

  • Hyoscine butylbromide is typically administered during the active phase of labor (not throughout pregnancy) 1
  • The standard dose is 40 mg as a slow intravenous injection 1

Not a Primary Antiemetic in Pregnancy

While hyoscine compounds have antiemetic properties, they are not recommended as first-line agents for nausea and vomiting in pregnancy. For pregnancy-related nausea:

  • First-line options include vitamin B6, doxylamine, and promethazine 6, 7
  • Metoclopramide is preferred as a second-line agent 6, 7
  • Phenothiazines like prochlorperazine are reserved for severe, intractable cases 6

Clinical Bottom Line

Hyoscine butylbromide serves a specific obstetric purpose: accelerating labor and providing analgesia during active labor through its cervical spasmolytic effects, with demonstrated safety for both mother and neonate 1, 3. It is not used for routine pregnancy symptoms but rather as an active labor management tool.

References

Research

Role of hyoscine N-butyl bromide (HBB, buscopan) as labor analgesic.

Indian journal of medical sciences, 2008

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Safety of Prochlorperazine During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safety of Promethazine DM During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.